Abstract
INTRODUCTION
Colorectal cancer (CRC) is the most common mali gnancy of the gastrointestinal (GI) tract; it is the second most common cancer in women and third in men [1] . Its incidence shows substantial geographical variation, resulting in a 10fold difference between some countries [1] . The high number of patients with CRC, precancerous lesions or polyps causes significant challenges to national healthcare systems, their chances to recognize tumors at an early stage, as well as possibilities to offer the most effective treatment. According to recent data the incidence of CRC is rising in many traditionally lowincidence countries like Japan, Korea, China, and Eastern Europe, which is thought to be a result of cultural and dietary changes towards a Western lifestyle [1] . Even though the overall incidence is increasing, at the same time some positive development has occurred in many previous high risk countries due to more effective diagnostics and treatment.
CRC usually develops from precursor lesions, i.e., colonic adenomas [2] . The prevalence of adenomas clearly increases by age. Postmortem studies indicate that 30%40% of individuals from Western countries have adenomas, most of them asymptomatic [3] .
A majority of these are benign and never turn malignant [2] . In familial syndromes, younger patients develop adenomas which proceed to cancer with a much higher frequency [24] . Removal of precancerous lesions at colonoscopy prevents them from proceeding to cancer. Thus, early diagnosis and complete removal of precancerous lesions are key factors for successful outcome.
The diagnostic arsenal in CRC includes several clinicopathological parameters, which can be utilized to determine the malignancy and prognosis. They include tumor stage according to the TNM (tumor, nodes, metastasis), Dukes or AstlerColler classification, as well as tumor grade, microsatellite instability, and molecular markers, recently reviewed by Marzouk and Schofield [5] . The intensively studied molecular markers include such as tumor suppressor gene p53 and its mutations as well as antigen Ki67 [6, 7] . However, new biomarkers are urgently needed to predict survival and improve stratification of CRC patients for different treatment options.
Carbonic anhydrases (CAs) constitute a group of zincbinding enzymes, which catalyze the reversible hydration of CO2 to bicarbonate. This reaction is crucial for maintenance of pH homeostasis of the body. Through this chemical reaction they are involved in several downstream physiological processes, such as bone resorption, vision, and production of saliva, bile, pancreatic juice and gastric juice [810] . The mammalian alphaCA family includes 16 known isoforms of which 15 can be found in humans. These isoforms show marked differences in their kinetics and cellular and subcellular distributions [8, 9] . Under hypoxic conditions cells produce acidic metabolic products via anaerobic glycolysis. This pathway is inhibited in the presence of enough oxygen. Notably, tumor cells have a tendency to upregulate glucose intake and increase the rate of anaerobic glycolysis even when the amount of oxygen is sufficient [11] . Tumor cells need CA enzymes and many other proteins, such as ion transporters, to maintain neutral intracellular pH [12] . During this process extracellular pH decreases, which in turn, disturbs physiological processes of the surrounding normal tissue and promotes cancer growth [11, 13] . Indeed, increased glucose intake and hypoxia are often linked to more aggressive and invasive tumor growth, signs that correlate with poor prognosis [11] . It has been suggested that partial hypoxia may contribute to cell selection, favoring a shift from a premalignant phenotype to more malignant forms, in which the oxygen free meta bolism plays a major role in making it possible for cells to survive in challenging hypoxic environments [11] . During the last 20 years, CA proteins have been studied as potential markers for various cancers. Cytosolic CA Ⅱ is the most widely expressed isoform in normal tissues, such as gastric, pancreatic, biliary, and intestinal epithelia [9, 14] . It is often absent or only weakly expressed in malignant tumors. Recently, CA Ⅱ was shown to be highly overexpressed in gastrointestinal stromal tumors, and it was suggested as a potential biomarker for this mesenchymal tumor type [15] . CA Ⅶ, another cytosolic isozyme, shows a more restricted tissue distribution than CA Ⅱ. It is predominantly expressed in the brain, where it contributes to bicarbonatedriven GABAergic excitation [16] . A recent study showed that CA Ⅶ is overexpressed in glioblastomas, suggesting that it may represent another tumorassociated CA isoform [17] . CA Ⅸ has attracted lots of attention, because its expression is limited to few normal tissues, such as gastric, intestinal and gall bladder epithelia, but it is highly overexpressed in hypoxic tumors [9, 18, 19] . CA XII is another isoform, which is overexpressed in several cancers, even though it is also present in various normal tissues. It has been demonstrated to be present in both normal intestinal epithelium and malignant colorectal tumors [9, 19, 20] . CA Ⅸ and XII are known to be regulated via von Hippel Lindau / hypoxia inducible factor pathway [21] . The aim of this study was to investigate the expression of isozymes CA Ⅱ, CA Ⅶ, CA Ⅸ, and CA XII in CRC. The immunohistochemical expression levels were correlated to clinicopathological data. Our results show that both CA Ⅱ and CA XII staining intensities correlate with survival rate of CRC patients, suggesting a potential role of these enzymes as prognostic biomarkers.
MATERIALS AND METHODS

Patients
In total, 840 patients underwent surgery for CRC at Helsinki University Hospital during years 19832001. Tissue specimens and clinical data from 645 patients were available for our study. These tumors were classified with Dukes classification which was a standard classification system during the sample collection period. 
Immunohistochemical analysis
Tumor samples were arranged as tissue microarrays. Three parallel series included one tumor sample each taken with a 1 mm needle. Of 645 patient samples we obtained, 106 ended up with no scoring results, because samples were washed out or displaced during the staining process. The remaining 539 samples were considered representative enough to be analyzed and scored. Each microscope slide contained four spots of normal human pancreas as positive controls. Five µm sections of formalinfixed paraffin embedded tumor specimens were deparaffinised and immunostained with rabbit antihuman CA Ⅱ, CA Ⅶ, and CA XII sera or with monoclonal antihuman CA Ⅸ antibody (M75). These antibodies have been previously announced as number of patients and percentage of patients, the KaplanMeier mean survival time with 95%CI, and the Cox regression hazard ratios with their 95%CI. P values < 0.05 were considered statistically significant. Two-tailed tests were used. KaplanMeier analysis and Cox regression hazard ratio model were used to analyze survival data. The assumption of constant hazard ratios over time was tested by including a time dependent covariate for each testable variable. Because neither Dukes classification nor histological differentiation grade status followed the Cox model assumption, stratified analyses for Dukes stage and differentiation grade were used. For statistical analyses, Dukes stage A and B, as well as C and D were combined to reduce the number of groups to two. The same was done for tumor differentiation status; low and medium low differentiations were combined as well as medium high and high differentiations. In the Cox proportional hazards model we included variables for age, sex, and site of the tumor. Separate analyses were made for each CA staining. If a significant interaction with CA staining and another parameter were found, a split analysis was performed.
In analysis, male patients were compared to females and 65 yearsold or older patients were compared to younger ones. Tumor location was also considered in the analysis: right side of the colon including the caecum, ascending colon and right flexure versus left side of the colon, including the left flexure, descending colon, sigmoid colon and rectum. Mid transverse tumors were excluded from the comparison.
When analyzing the expression of each CA enzyme, level 0 was considered the baseline, and the anno unced hazard ratio rises exponentially every time the scoring value rises one unit. Statistical analyses were performed by SPSS v 21© (IBM corp, New York).
RESULTS
Four CA isozymes, CA Ⅱ, Ⅶ, Ⅸ, and XII were selected for the immunohistochemical analysis of colorectal cancer and the summary of these results is presented in Table 2 . Figure 1 presents representative images utilized in numerous studies and are specific for each isozyme [2225] . Immunoperoxidase staining was performed in an automated Lab Vision Autostainer 480 (LabVision Corporation, Fremont, CA, United States) by Power Vision+ PolyHRP Immunohistochemistry kit reagents (ImmunoVision Technologies Co) inclu ding the following steps: (1) rinsing in wash buffer; (2) treatment in 3% H2O2 in ddH2O for five minutes and rinsing with wash buffer; (3) blocking with cow colostrum diluted 1:2 in Trisbuffered saline containing 0.05% Tween20 for 30 min and rinsing in wash buffer; (4) incubation with primary antibody (polyclonal antibodies diluted 1:2000 and monoclonal M75 diluted 1:100) for 30 min; (5) rinsing in wash buffer three times for five minutes; (6) incubation in polyHRPconjugated antirabbit/mouse IgG for 30 min and rinsing in wash buffer three times for five minutes; (7) incubation in DAB (3,3'diaminobenzidine tetrahydrochloride) solution (one drop of DAB solution A and one drop of DAB solution B in 1 mL of ddH2O) for six minutes and rinsing in ddH2O; (8) CuSO4 treatment for five minutes to enhance the signal and rinsing in ddH2O; (9) treatment with hematoxylin for one minute; and (10) rinsing with ddH2O. All procedures were performed at room temperature. The mounting of the sections was performed using Entellan Neu (Merck; Darmstadt, Germany) and was finally examined and photographed with a Zeiss Axioskop 40 microscope (Carl Zeiss; Göttingen, Germany). The intensity of the staining was scored on a scale of 0 to 3 as follows: 0, no reaction; 1, weak reaction; 2, moderate reaction; 3, strong reaction. The extent of the staining was scored as 1 when 1%10% of the cells stained, 2 when 11%50% of the cells stained, and 3 when 51%100% of the cells stained. A negative score (0) was given to tissue sections that had no evidence of specific immunostaining. In addition to the analysis of tumor cells, CA Ⅱ immunostaining was also evaluated in endothelial cells and CA Ⅶ in tumor stroma, because these enzymes showed significant staining reactions in these specific locations.
Statistical analysis
All statistical analyses were performed by an expe rienced biostatistician (H. Mustonen). Results are In Cox regression analysis, the most significant results were found for CA Ⅱ staining intensity as shown in Table 3 . One unit increase in the CA Ⅱ intensity increased the age, sex, Dukes, differentiation, and tumor side corrected hazard ratio to 1.19 fold (95%CI: 1.041.37, P = 0.009). However, no significant interaction was found between CA Ⅱ intensity and age, sex, or location of tumor. When extent of the CA Ⅱ staining was analyzed a significant interaction between age group and extent of the CA Ⅱ staining was found. Therefore, the analysis was split between the age groups. This revealed that increased extent of CA Ⅱ had a significant hazard ratio among patients 65 years and older (1.42, 95%CI: 1.161.73, P = 0.0006). Notably, in addition to the actual tumor cells, CA Ⅱpositive staining was often induced in the endothelium of tumor capillaries. In KaplanMeier analysis, vascular endothelial staining of CA Ⅱ did not show any significant correlation to survival (P = 0.676).
Epithelial CA Ⅶ immunostaining showed no correlation to patients' survival ( Figure 2) . In Kaplan Meier survival analysis, P values were 0.566 for staining intensity and 0.495 for extent. Negative results were also observed for stromal staining (P = 0.816 for intensity; P = 0.591 for extent). There was a significant correlation (P = 0.013) between epithelial staining extent and Dukes classification. These results are shown in Table 4 . No significant correlation was found between epithelial or stromal CA Ⅶ immunostaining and other parameters.
In Kaplan-Meier analysis no significant correlation was found between survival and intensity (P = 0.879) or extent (P = 0.315) of CA Ⅸ immunostaining. Additionally, no correlation was found when the CA Ⅸ immunostaining was compared with the other tumor or clinical parameters.
In KaplanMeier analysis, CA XII was another isozyme showing a significant correlation to survival. The mean survival time decreased from 16.5 years (95%CI: 13.719.2) to 9.9 years (95%CI: 7.312.4) as the intensity of CA XII increased from 0 to 3. In Cox regression analysis, a significant correlation was found when comparing CA XII staining intensity with survival of CRC patients (HR = 1.18, 95%CI: 1.011.38, P = 0.036; Table 3 ). There was no significant interaction between CA XII intensity and age, gender or location of the tumor. The extent of CA XII immunostaining did not correlate to the patients' survival (P = 0.242, KaplanMeier analysis). CA XII staining extent did not either correlate with clinicopathological parameters.
In general, patients 65 years and older had a significantly increased risk for poorer survival (HR = 1.78, 95%CI: 1.352.34, P < 0.0001 in CA Ⅱ epithelium intensity analysis and 1.67, CI: 1.272.19, P = 0.0002 in CA XII epithelium intensity analysis). 
DISCUSSION
In our study, the expression of carbonic anhydrase isozymes CA Ⅱ and CA XII correlated with patients' survival. Our results suggest that these proteins might have a value in the assessment of CRC patients, specifically when selecting patients for a more aggressive cancer treatment. Patients with a better prognosis can be treated less aggressively, which diminishes side effects and increases quality of life. The obtained hazard rations were relatively modest, and thus the results need to be interpreted with caution.
According to our results, CA Ⅸ has no diagnostic or prognostic role in CRC, even though it has been considered a promising biomarker for several other cancers [26] . This finding highlights the unique biology of CRCs in terms of tumor development process.
The role of different CA isozymes in cancer has been under intensive research during the last decade. Studies have been focused on the association between expression of CAs and tumor aggressiveness and patient survival, on their role in tumor metastasis, as well as on their potential role as targets of anticancer drugs [13, 2729] . CA isozymes have shown abnormal expression in various malignant tumors compared to corresponding normal cells and tissues [11, 13, 17, 2931] .
In one study, CA Ⅸ was shown to be diffusely expressed in CRC, whereas normal or adenomatous mucosa showed a more limited distribution [18] . Ki67
immunostainings confirmed that CA Ⅸ was expressed in areas with high proliferative activity. Similarly, CA XII showed a more diffuse immunostaining reaction in CRC compared to normal colon or adenomas [20] . Cytosolic CA Ⅱ isozyme has a different distribution. It is highly expressed in several normal gastrointestinal tract tissues, such as gastric and intestinal mucosa [14] , but is clearly downregulated in most colorectal tumors [32] . The same phenomenon may also occur in the case of the other cytosolic CAs [33] . According to Birkenkamp Demtroder's study [34] , CA Ⅶ expression was found to be 4fold downregulated in sigmoid or rectosigmoid carcinomas compared to the normal tissue. Recently, Niemelä et al [35] reported cDNA microarray expression of all CAs, except for CA XIII, in normal and malignant colorectal specimens. The foldchanges for our target CA isozymes were: CA Ⅱ [7.4 (normal mucosa vs sporadic carcinoma)], CA Ⅶ (4.3), CA Ⅸ (+2.4) and CA XII (3.2). In our Figure 1 increased expression is clearly demonstrated for CA Ⅸ, whereas the interpretation is more difficult for the other isozymes because of high staining intensities in both normal and tumor tissues. Even though the pathogenesis of colorectal cancer has been intensively studied during the last decades, there are still molecular mechanisms that clearly warrant more research. For example, it was recently shown that polyps with any advanced neoplastic features are smaller in the right side of the colon than in the left side, and the gene expression is also different [34, 36] . In our study, however, the reactivity of CA enzymes showed no correlation to the tumor location.
The main clinicopathological factors affecting colorectal cancer patients' survival are tumor grade, resection margins, and presence or absence of lymph node metastases [3] . Other factors with prognostic significance include tumor budding, micrometastases, peritoneal carcinomatosis, lymphatic, perineural and venous invasion, and histological properties including level of invasion [5] . In Marzouk and Schofield's review [5] , a number of potential prognostic molecular markers, such as microsatellite instability, BRAF mutation, KRAS mutation, PIK3CA mutations, and PTEN deletion, were evaluated. 18q deletions and thymidylate synthase expression have been associated with unfavorable prognosis and tumor recurrence [5] . Even though many of these molecular markers have been used when choosing patients with metastatic disease for chemotherapy [5] , new markers are still needed to distinguish different cancer types or to stratify patients for personalized chemotherapy according to the cancer properties. Further studies are needed to define the clinical value of CA Ⅱ and CA XII staining for preoperative evaluation and for comparison of these markers in colorectal cancer.
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COMMENTS
Background
Colorectal cancer (CRC) is the most common malignancy of the gastrointestinal tract. The high number of patients with CRC, precancerous lesions or polyps causes significant challenges to healthcare systems, their chances to recognize tumors at an early stage, as well as possibilities to offer the most effective treatment. Tumor cells need carbonic anhydrases (CAs) and many other proteins, to maintain neutral intracellular pH. During tumor growth extracellular pH decreases and disturbs physiological processes of the surrounding normal tissue and promotes cancer growth. This is why CA proteins have been studied as potential markers for various cancers.
Research frontiers
CA Ⅱ and CA XII staining intensities correlated with colorectal cancer patients' survival in that higher expression indicated poorer prognosis.
Innovations and breakthroughs
The correlation of both CA Ⅱ and CA XII staining results with survival of colorectal cancer patients was a novel observation. Surprisingly, CA Ⅸ immunostaining results did not show any correlation to patients' prognosis, even though this enzyme is widely considered a potential predictive marker in several other tumor categories.
Applications
These results suggest that CA Ⅱ and CA XII proteins might be valuable in COMMENTS assessment of CRC patients, specifically when selecting patients for a more aggressive cancer treatment. Patients with a better prognosis can be treated less aggressively, which diminishes side effects and increases quality of life.
Terminology
CAs are a group of zinc-binding enzymes, which catalyze the reversible hydration of CO2 to bicarbonate.
Peer-review
Biomarkers for colorectal Cancer are still under intense Investigation and novel predictive and prognostic markers are urgently needed. The authors investigate the Protein Expression Levels of several CA in a large series of colorectal cancer and conclude that CA Ⅱ and CA XII could be useful prognostic markers.
